We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PLXS Stock Up 32% in 3 Months: Is There Further Upside Left?
Read MoreHide Full Article
Key Takeaways
Plexus stock jumped 32.3% in 3 months, outperforming peers and broader market declines.
PLXS logged 22 wins worth $283M in Q1, with strength across aerospace, defense and healthcare end markets.
Plexus sees program wins, share gains, and stronger demand driving revenue to meet/exceed the 9-12% range.
Plexus Corporation (PLXS - Free Report) has emerged as a compelling performer in the electronics manufacturing services (EMS) space, with the stock price appreciating 32.3% over the past three months, outperforming the Electronic Manufacturing Industry’s growth of 8.7%. The S&P 500 composite and the broader Computer Technology Sector have declined 4.8% and 6.7%, respectively.
Price Performance
Image Source: Zacks Investment Research
Other players in the electronics manufacturing services space, like Jabil (JBL - Free Report) and Flex Ltd. (FLEX - Free Report) , have gained 13.1% and 3.5%, respectively, while Sanmina Corporation (SANM - Free Report) is down 14.8%.
Given this backdrop, the question for investors is straightforward: after this rally, does PLXS still offer compelling long-term upside?
Let us take a closer look at PLXS fundamentals, growth drivers, competitive advantages and potential risks and assess whether it is still a buy?
Multiple Tailwinds Offer Runway for Long-Term Growth
A healthy number of program ramps are expected to drive the top-line performance for Plexus. The company is focusing its efforts on sectors with robust demand, such as healthcare and life sciences, aerospace and defense, and industrial markets, especially semicap and energy management subsectors.
In the first quarter of fiscal 2026, Plexus announced 22 manufacturing program wins, which are estimated to contribute $283 million in annualized revenues once fully ramped into production. For fiscal 2025, Plexus had 141 manufacturing wins totaling $941 million in annualized revenues.
Notably, the Aerospace and Defense sector delivered record $220 million in the fiscal first quarter wins and Healthcare/Life Sciences had $40 million. Management highlighted that program wins, share gains and strengthening market demand position it for meeting/exceeding the high end of 9% to 12% total revenue growth target for fiscal 2026. The funnel of qualified manufacturing opportunities is $3.6 billion, indicating a strong pipeline for growth. The company had a record funnel for its Aerospace and Defense end market segment.
For both Aerospace and Healthcare/Life Sciences segments, PLXS expects to exceed the 9-12% range.
Further, strong cash flow generation bodes well. Plexus is driving free cash flow generation through a combination of operational/capex discipline and inventory reduction. While fiscal first-quarter free cash flow was negative due to investments, Plexus reaffirmed its fiscal 2026 free cash flow target of $100 million, underscoring working capital efficiency. Strong cash flow generation positions Plexus to maximize shareholder value via buybacks and reduce debt. It repaid $100 million of debt in fiscal 2025.
On the last earnings call, management emphasized that all excess cash will be used to create shareholder value. The company repurchased $22.4 million worth of shares at an average price of $146.36 per share under its repurchase program. Out of the $100 million authorization, $62.6 million remains available. For fiscal 2025, it repurchases $65 million worth of shares. The robust cash generation ensures that Plexus has a healthy financial foundation to support growth and investment in the business.
The company’s business strategy, focusing on earning a return on invested capital (“ROIC”) that exceeds its weighted average cost of capital (“WACC”), bodes well. For the first quarter of fiscal 2026, the company’s after-tax ROIC reached 13.2%, 420 bps above the WACC of 8.9%.
However, no investment case is without risks. The challenges in the Industrial sector in the near term remain concerning. Fiscal first-quarter revenues declined 8% sequentially. Growth recovery is heavily dependent on semicap demand rebound and program ramps in the industrial equipment subsector, while other industrial subsectors continue to face softness. If the semicap cycle stalls or weakens again, the Industrial segment could remain a drag on consolidated growth. Management expects fiscal 2026 revenues for this sector to approach the 9% to 12% target range.
Macro uncertainty owing to shifting trade policy and stiff competition in the EMS space from FLEX, Jabil and Sanmina are additional concerns.
Image Source: Zacks Investment Research
Given all these factors, analysts have revised PLXS’ estimates up for the current quarter and year.
PLXS Valuation
In terms of the forward 12-month price/earnings ratio, PLXS is trading at 24.58, slightly above the sector’s multiple of 23.43.
Image Source: Zacks Investment Research
In comparison, FLEX, Jabil and Sanmina trade at a forward 12-month P/E of 18.2X, 20.57X and 11.84X, respectively.
How to Play PLXS Stock?
Plexus’ robust pipeline of program wins, expanding exposure to end markets like aerospace, defense and healthcare, and a solid $3.6 billion opportunity funnel provide improved visibility into sustained revenue growth. Coupled with healthy cash generation supporting buybacks, PLXS remains well-positioned for further upside despite near-term industry headwinds.
View the Zacks #1 Rank List
Image: Bigstock
PLXS Stock Up 32% in 3 Months: Is There Further Upside Left?
Key Takeaways
Plexus Corporation (PLXS - Free Report) has emerged as a compelling performer in the electronics manufacturing services (EMS) space, with the stock price appreciating 32.3% over the past three months, outperforming the Electronic Manufacturing Industry’s growth of 8.7%. The S&P 500 composite and the broader Computer Technology Sector have declined 4.8% and 6.7%, respectively.
Price Performance
Image Source: Zacks Investment Research
Other players in the electronics manufacturing services space, like Jabil (JBL - Free Report) and Flex Ltd. (FLEX - Free Report) , have gained 13.1% and 3.5%, respectively, while Sanmina Corporation (SANM - Free Report) is down 14.8%.
Given this backdrop, the question for investors is straightforward: after this rally, does PLXS still offer compelling long-term upside?
Let us take a closer look at PLXS fundamentals, growth drivers, competitive advantages and potential risks and assess whether it is still a buy?
Multiple Tailwinds Offer Runway for Long-Term Growth
A healthy number of program ramps are expected to drive the top-line performance for Plexus. The company is focusing its efforts on sectors with robust demand, such as healthcare and life sciences, aerospace and defense, and industrial markets, especially semicap and energy management subsectors.
In the first quarter of fiscal 2026, Plexus announced 22 manufacturing program wins, which are estimated to contribute $283 million in annualized revenues once fully ramped into production. For fiscal 2025, Plexus had 141 manufacturing wins totaling $941 million in annualized revenues.
Notably, the Aerospace and Defense sector delivered record $220 million in the fiscal first quarter wins and Healthcare/Life Sciences had $40 million. Management highlighted that program wins, share gains and strengthening market demand position it for meeting/exceeding the high end of 9% to 12% total revenue growth target for fiscal 2026. The funnel of qualified manufacturing opportunities is $3.6 billion, indicating a strong pipeline for growth. The company had a record funnel for its Aerospace and Defense end market segment.
For both Aerospace and Healthcare/Life Sciences segments, PLXS expects to exceed the 9-12% range.
Further, strong cash flow generation bodes well. Plexus is driving free cash flow generation through a combination of operational/capex discipline and inventory reduction. While fiscal first-quarter free cash flow was negative due to investments, Plexus reaffirmed its fiscal 2026 free cash flow target of $100 million, underscoring working capital efficiency. Strong cash flow generation positions Plexus to maximize shareholder value via buybacks and reduce debt. It repaid $100 million of debt in fiscal 2025.
Plexus Corp. Price, Consensus and EPS Surprise
Plexus Corp. price-consensus-eps-surprise-chart | Plexus Corp. Quote
On the last earnings call, management emphasized that all excess cash will be used to create shareholder value. The company repurchased $22.4 million worth of shares at an average price of $146.36 per share under its repurchase program. Out of the $100 million authorization, $62.6 million remains available. For fiscal 2025, it repurchases $65 million worth of shares. The robust cash generation ensures that Plexus has a healthy financial foundation to support growth and investment in the business.
The company’s business strategy, focusing on earning a return on invested capital (“ROIC”) that exceeds its weighted average cost of capital (“WACC”), bodes well. For the first quarter of fiscal 2026, the company’s after-tax ROIC reached 13.2%, 420 bps above the WACC of 8.9%.
However, no investment case is without risks. The challenges in the Industrial sector in the near term remain concerning. Fiscal first-quarter revenues declined 8% sequentially. Growth recovery is heavily dependent on semicap demand rebound and program ramps in the industrial equipment subsector, while other industrial subsectors continue to face softness. If the semicap cycle stalls or weakens again, the Industrial segment could remain a drag on consolidated growth. Management expects fiscal 2026 revenues for this sector to approach the 9% to 12% target range.
Macro uncertainty owing to shifting trade policy and stiff competition in the EMS space from FLEX, Jabil and Sanmina are additional concerns.
Image Source: Zacks Investment Research
Given all these factors, analysts have revised PLXS’ estimates up for the current quarter and year.
PLXS Valuation
In terms of the forward 12-month price/earnings ratio, PLXS is trading at 24.58, slightly above the sector’s multiple of 23.43.
Image Source: Zacks Investment Research
In comparison, FLEX, Jabil and Sanmina trade at a forward 12-month P/E of 18.2X, 20.57X and 11.84X, respectively.
How to Play PLXS Stock?
Plexus’ robust pipeline of program wins, expanding exposure to end markets like aerospace, defense and healthcare, and a solid $3.6 billion opportunity funnel provide improved visibility into sustained revenue growth. Coupled with healthy cash generation supporting buybacks, PLXS remains well-positioned for further upside despite near-term industry headwinds.
PLXS currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.